Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management

Haematologica

Volumn 95, Issue 7, 2010, Pages 1130-1135

  Gerlinger, Marco ^a   Rohatiner, Ama Z S ^a   Matthews, Janet ^a   Davies, Andrew ^a   Andrew Lister, T ^a   Montoto, Silvia ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Active surveillance; Clinical relapse; Follicular lymphoma; High dose therapy

Indexed keywords

CYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; RECURRENT CANCER; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; AUTOTRANSPLANTATION; BONE MARROW EXAMINATION; DISEASE MANAGEMENT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; TOMOGRAPHY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW EXAMINATION; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; TOMOGRAPHY; TRANSPLANTATION, AUTOLOGOUS;

EID: 77954467371     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.020115     Document Type: Article

References (14)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909-39018.
2. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13(1):140-147.
3. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007; 25(17):2426-2433.
4. Diagnostic Imaging in Lymphoma. Ontario: Cancer Care Ontario; 2006, 8 March.
5. Non-Hodgkin's Lymphoma: National Comprehensive Cancer Network; 2009 27/01/2009.
6. Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendationsfor diagnosis, treatment and follow-up. Ann Oncol. 2008; 19 (Suppl 2):ii77-88.
7. Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000;18(3):527-536.
8. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007; 25(18):2554-2559.
9. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984; 311(23):1471-1475.
10. Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large Bcell non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44(1):123-125.
11. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol. 2006; 17(6):909-913.
12. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting vaggressive combined modality treatment. Semin Hematol. 1988; 25(2 Suppl 2):11-16.
13. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Longterm effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003; 362(9383):516-522.
14. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3):1110-1117.